Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $49.1 million.

  • Entrada Therapeutics' Cash from Investing Activities rose 15921.96% to $49.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.1 million, marking a year-over-year increase of 32706.7%. This contributed to the annual value of -$27.8 million for FY2024, which is 7991.4% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Cash from Investing Activities of $49.1 million as of Q3 2025, which was up 15921.96% from $33.8 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Cash from Investing Activities peaked at $53.4 million during Q4 2024, and registered a low of -$181.5 million during Q1 2022.
  • In the last 4 years, Entrada Therapeutics' Cash from Investing Activities had a median value of $4.8 million in 2025 and averaged -$15.1 million.
  • In the last 5 years, Entrada Therapeutics' Cash from Investing Activities tumbled by 211907.95% in 2024 and then skyrocketed by 23860.89% in 2025.
  • Entrada Therapeutics' Cash from Investing Activities (Quarter) stood at $18.8 million in 2022, then rose by 1.34% to $19.0 million in 2023, then soared by 180.23% to $53.4 million in 2024, then dropped by 7.98% to $49.1 million in 2025.
  • Its Cash from Investing Activities was $49.1 million in Q3 2025, compared to $33.8 million in Q2 2025 and $4.8 million in Q1 2025.